EMA Publishes Safety Monitoring Guide

News
Article

The European Medicines Agency has published a guide to help industry and regulatory authorities implement safety-monitoring standards.

 

The European Medicines Agency (EMA) has published a guide on the implementation of the ISO Individual Case Safety Report (ICSR) standard, which improves the reporting of suspected side effects of medicines in ICSRs. The EMA guide was developed, jointly with the Heads of the Medicines Agency, to support pharmaceutical companies and medicines regulatory authorities in EU Member States in preparing for implementation of the ISO ICSR standard. According to EMA, the guide provides “definitions for the electronic transmission process of ICSRs, the format and content of the ICSR, the business rules for report validation as well as classification and data quality principles. It will also assist software providers and IT developers as pharmacovigilance databases are being developed.”

The ISO ICSR standard, which takes effect July 1, 2016, establishes a single format for the reports on individual cases of suspected side effects in patients due to a medicine across the world. The standard also includes adverse drug reaction information and information on the therapeutic uses of those medicines. The standard aims to improve the quality of data by strengthening personal data protection in the records of ICSRs collected by pharmaceutical companies and regulatory authorities.

Source: European Medicines Agency

Recent Videos
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments